NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2026)

NewAmsterdam Pharma has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $4.0 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $4.0 million, up 31.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 31.58% YoY), and the FY2025 annual result was $4.0 million, down 33.64% from the prior year.
• Current Deferred Revenue came in at $4.0 million for Q1 2026 at NewAmsterdam Pharma, roughly flat from $4.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q4 2022 to a low of $3.0 million in Q1 2025.
• The 5-year median for Current Deferred Revenue is $6.0 million (2024), against an average of $7.1 million.
• Across the five-year window, Current Deferred Revenue tumbled 62.67% in 2025 and jumped 31.58% in 2026, its largest moves.
• NewAmsterdam Pharma's Current Deferred Revenue stood at $18.7 million in 2022, then plunged by 46.64% to $10.0 million in 2023, then sank by 39.68% to $6.0 million in 2024, then slumped by 33.64% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $4.0 million (Q1 2026), $4.0 million (Q4 2025), and $3.0 million (Q1 2025), per Business Quant data.